BIODAN SCIENCES S.L.

About Biodan Sciences, SL

Created in 2011 this company has as objective to supply the most advanced natural ingredients, through liberation mechanisms that are more efficient than the ones provided by the ingredients obtained by traditional chemistry.
For this, Bioadan applies the latest advances in the field of immunology and the applied biotechnology to active ingredients extracted from plants. The founding values for the generation of these innovative products are: the use of very advanced technologies, the search for a greater efficiency, and the use of safe natural products that are produced and developed in an ethical way.

Investment in Biodan Sciences, S.L.

In November 2013 InKemia enters the company Bioadan Sciences with an investment of 240.000 €. This contribution gave InKemia a share of 19% of Biodan’s capital with the possibility of becoming a 21% in the next years.

BIODAN SCIENCES S.L.

ENEMCE PHARMA

About Enemce Pharma, S.L:

Enemce Pharma is a classic Drug Discovery company created with the objective of developing a new candidate for medicines for preventing cardiovascular diseases.

Ivestment in Enemce Pharma

In November 2012, the knowledge capital fund makes a second round of investments in the company Enemce Pharma, with an initial contribution of 5.500 €., in the beginning of 2014 a second contribution of another 5.400 €. was made.
These contributions have as an objective the development of a first stage of proof of concept, in case this is successful new stages and investments would be develop.

ENEMCE PHYTURE PHARMA

PHYTURE BIOTECH

About Phyture Biotech, SL

Created in 2009 as a spin-off of the Pharmacy Faculty of the University of Barcelona, Phyture Biotech bases all of its activities in its technological platform of vegetable cell culture. With this technology one can modify the metabolism of the cells to obtain innovative extracts of high added value and that are more efficient and safe than the traditional ones. Phyture Biotech is a pioneer in the application of this technology in the industry.
On the one hand a new range of products is being developed based on the culture of unique vegetal cells. These products will then become active ingredients destined to the cosmetic, dermatologic and pharmaceutical industry.
On the other hand, researches are being carried out to optimize the technology in the production of recombinant proteins. Even thought currently they are not commonly used, the vegetable cells have a great potential in this sector because of their unique characteristics.

Investment in Phyture Biotech S.L

In the BioSpain congress in 2012 an agreement of investment was presented by the Knowledge capital fund for the company Phyture Biotech S,L, becoming the first company where the fund invested. InKemia entered this biotechnological company with an investment of 270.000 € participating with 21,26% in its capital

ENEMCE PHARMA

About Enemce Pharma, S.L:

Enemce Pharma is a classic Drug Discovery company created with the objective of developing a new candidate for medicines for preventing cardiovascular diseases.

Ivestment in Enemce Pharma

In November 2012, the knowledge capital fund makes a second round of investments in the company Enemce Pharma, with an initial contribution of 5.500 €., in the beginning of 2014 a second contribution of another 5.400 €. was made.
These contributions have as an objective the development of a first stage of proof of concept, in case this is successful new stages and investments would be develop.

BIODAN SCIENCES S.L.

About Biodan Sciences, SL

Created in 2011 this company has as objective to supply the most advanced natural ingredients, through liberation mechanisms that are more efficient than the ones provided by the ingredients obtained by traditional chemistry.
For this, Bioadan applies the latest advances in the field of immunology and the applied biotechnology to active ingredients extracted from plants. The founding values for the generation of these innovative products are: the use of very advanced technologies, the search for a greater efficiency, and the use of safe natural products that are produced and developed in an ethical way.

Investment in Biodan Sciences, S.L.

In November 2013 InKemia enters the company Bioadan Sciences with an investment of 240.000 €. This contribution gave InKemia a share of 19% of Biodan’s capital with the possibility of becoming a 21% in the next years.

PLASMIA BIOTECH

MIND THE BYTE

LEAN BIO

Type of projects in which the fund invests
The fund is destined to companies that have not yet being created or are recently so, with an elevated potential for growth and an innovative and technological foundation.  
The investment is done in the following fields:
•    Green Chemistry
•    Biofuels
•    Industrial Biotechnology
•    Fine Chemistry
•    Drug Discovery
•    Drug Delivery
•    Drug Development
•    Biomedicine
•    Pharmaceutical industry
•    Cosmetics
•    Functional Food industry
A key element of investment that the fund makes is the possibility of creating synergies with the technological and scientific capacity of innovation of InKemia.
The finality of the resources provided by the fund would be to achieve technological development of the company, by giving it direct access to InKemia’s resources:
•    Scientific know-how
•    Technological equipment and facilities
•    Technological analytical services
•    Consultancy in projects and institutional relationships
•    Access to highly specialized information

The Fund is managed by IUCT Emprèn, one of the companies of InKemia IUCT group born in 1997. InKemia is a holding of 4 companies, in the biotechnological sector, that generate high value knowledge destined to be sold to the chemical and pharmaceutical industries.
InKemia’s business model is different from the rest of other biotechnological companies because our objective is to generate a know-how of added value to be commercialized in multiple ways: technological transfer of the product to the industry (licensing patents), use of the generated knowledge through “contract research” with companies of the sector, sale of projects to public organisms in order to obtaining grants, use of technological equipments acquired during the project for providing technological services, generation of new R&D projects, technical consultancy, masters degree and post-graduate specialized studies, creation of new technological platforms. On the other hand, the traditional biotechnological companies have as their objective to create a technological product for its direct commercialization.
The facilities and laboratories of InKemia are located in Mollet del Vallés (Barcelona) and it also counts with a space in the technological park Tres Cantos in Madrid, Vilanova I la Geltrú (Barcelona) and a commercial venue in Sao Paulo (Brazil)
In 2011 InKemia started a strategic process of entrepreneur encouragement. In this process the launch of the knowledge capital fund and other tools such as the Entrepreneurial program as part of our master’s degree courses.

This is a seed capital fund through which InKemia puts in disposition for the entrepreneurs a new financial tool so that they can launch their innovative project.

This fund is born under the strategic perspective of “Open Innovation”. The main characteristic that defines it, is that it is not a fund targeted exclusively to providing financial funds to a new company, but that it expects to contribute further with the value of knowledge, experience and technology that InKemia has to offer.

The fund has 4 million Euros to invest in 10 years with an investment volume per transaction between 50 K and 400 K Euros, being the average in 200K Euros.

The objective is to be able to participate in 2 annual transactions.

The participation in the company’s shares will be minority.

The disinvestments are planned in the mid and long term, and are in every case agreed with the entrepreneur. There is no maximum term of disinvestment.